CAPR - Company ID 0001133869
The table below shows CAPRICOR THERAPEUTICS, INC.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | $2.26M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $28.87M | $27.38M | $20.36M | $22.05M | $18.92M | $11.81M |
| SG&A |
CAPRICOR THERAPEUTICS, INC. reported annual revenue of $0.00 for fiscal year 2025. That is down 100.0% from $22.27M in fiscal 2024. Over the 10 fiscal years shown, annual revenue declined from $4.00M (FY 2016) to $0.00. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $14.08M |
| $9.40M |
| $5.92M |
| $5.67M |
| $6.07M |
| $3.46M |
| Operating income | -$42.95M | -$36.77M | -$26.28M | -$27.72M | -$24.98M | -$13.01M |
| Income tax | $1.60K | $0.00 | - | $1.60K | $0.00 | - |
| Net income | -$40.73M | -$33.94M | -$24.57M | -$25.91M | -$24.39M | -$12.56M |
| EPS (diluted) | -$0.70 | -$0.59 | -$0.54 | -$0.57 | -$0.53 | -$0.38 |